Oncology
Refine search
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-322 trial. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Biotechnology
Anglo-Irish biopharma SynOx Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) patients that are not amenable to or who would not benefit from surgery. 14 April 2026
Biotechnology
Dutch biotech Laigo Bio, which is pioneering novel and highly differentiated therapies using its proprietary SureTACs precision membrane protein degradation platform, has appointed Dr Richard Sainson as its new chief scientific officer (CSO). 14 April 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading. 13 April 2026
Pharmaceutical
Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. 13 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Biotechnology
UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. 13 April 2026
Biotechnology
Chinese clinical-stage biotech OriCell Therapeutics announced the cumulative closing of a pre-initial public offering (IPO) financing round in excess of $110 million. 13 April 2026
Biotechnology
US biotech Replimune has suffered a fresh blow after the US Food and Drug Administration rejected its lead cancer therapy RP1 (vusolimogene oderparepvec), sending shares sharply lower and casting doubt over the program’s future. 13 April 2026
Pharmaceutical
Swiss pharma giant Novartis today posted financial results, showing that fourth-quarter 2025 net sales were $13.3 billion (+1%, -1% constant currency - cc), with volume contributing 18 percentage points to growth. Generic competition had a negative impact of 15 percentage points, the company noted. 4 February 2026
Pharmaceutical
British drugmaker GSK has reported higher revenue and earnings for both the fourth quarter and full year, reflecting strong demand for HIV and specialty medicines. Fourth-quarter revenue rose 6% to £8.6 billion (about $10.9 billion), while earnings per share increased 56%. 4 February 2026
Pharmaceutical
US pharma giant Merck & Co has announced financial results for the fourth quarter and full year of 2025. 3 February 2026
Pharmaceutical
Cambridge, USA-based precision medicines specialist Relay Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to zovegalisib (RLY-2608). 3 February 2026
Pharmaceutical
Pfizer posted fourth-quarter 2025 revenue of about $18 billion, down 1% from the year-ago quarter, and adjusted diluted earnings per share of $0.66, up 5%. For full-year 2025, revenue declined 2% to roughly $63 billion, with adjusted diluted EPS of $3.22, up 4%. 3 February 2026
Biotechnology
Cambridge, UK-based biotech Bicycle Therapeutics, which is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced leadership transitions for its next phase of innovation. 3 February 2026
Biotechnology
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics License Application (BLA) for Saphnelo (anifrolumab) for subcutaneous administration in adult patients with systemic lupus erythematosus (SLE). 3 February 2026
Pharmaceutical
Australian radiopharmaceutical company AdvanCell has entered into a collaboration and exclusive licensing deal with Canadian biotech 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic. 2 February 2026
Biotechnology
French immuno-oncology company Kahimmune Therapeutics has announced the signing of an exclusive licensing agreement with cancer research hospital Gustave Roussy and technology transfer specialist SATT Paris-Saclay. 2 February 2026
Pharmaceutical
Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating Erleada (apalutamide) without docetaxel experienced a statistically-significant 51% reduction in the risk of death. 2 February 2026
Biosimilars
The Delhi High Court in India has upheld the grant of a pharmaceutical patent to privately-held Swiss drugmaker Helsinn Healthcare for its nausea medication, an orally administered dosage form combining palonosetron (a 5-HT3 receptor antagonist) and netupitant (an NK1 receptor antagonist). 2 February 2026
Biotechnology
US biotech major Regeneron has presented its financial results for the fourth quarter and full year 2025. 30 January 2026
Biotechnology
USA-based mRNA vaccines company Moderna today announced that David Berman has been appointed as the company's chief development officer, beginning March 2, 2026. 30 January 2026
Biotechnology
The US Food and Drug Administration has accepted Summit Therapeutics’ application for ivonescimab plus chemotherapy in patients with EGFR-mutated non-small-cell lung cancer who have progressed after tyrosine kinase inhibitor treatment. A decision is due by mid-November. 30 January 2026
Pharmaceutical
Swiss pharma giant Roche achieved sales growth of 7% (2% in francs) to 61.5 billion francs ($48.8 billion) due to strong demand for pharmaceutical products and diagnostic solutions. 29 January 2026
Biotechnology
It is becoming evident that German oncology start-up CatalYm has a highly promising asset on its hands in the shape of visugromab, a first-in-class anti-growth differentiation factor-15 (GDF-15) antibody. 29 January 2026
Pharmaceutical
Japanese pharma Takeda reported revenue of about $21.8 billion for the nine months to December 31, down 3% year on year, while basic earnings per share rose 3% to roughly $0.88. Profit before tax increased 11%, supported by cost controls and lower financing expenses. 29 January 2026
Biotechnology
US biotech Gilead Sciences today announced that its Trodelvy (sacituzumab govitecan-hziy) has now been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a category 1 preferred first-line treatment option. 28 January 2026
Biotechnology
Japanese drugmaker Chugai today revealed it has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for the anti-cancer agent/humanized anti-PD-L1 monoclonal antibody Tecentriq (atezolizumab) 840mg Intravenous Infusion for an additional indication of adjuvant therapy for MRD-positive bladder cancer (MIBC). 28 January 2026
Biotechnology
The US Food and Drug Administration (FDA) yesterday approved daratumumab and hyaluronidase-fihj – trade name Darzalex Faspro - from Johnson & Johnson subsidiary Janssen Biotech, in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). 28 January 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze